Eurazeo (FR:RF) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kurma Partners has announced the first close at EUR 140 million for its new Biofund IV, with a target of EUR 250 million and plans to make 16 to 20 new investments in innovative therapeutics. The fund, which has already completed three investments, continues Kurma’s strategy of collaborating with academic and industry professionals to foster Europe’s health innovation ecosystem. With cornerstone investments from Eurazeo, Bpifrance, and CSL, and following successful exits from the Biofund III portfolio, the new fund demonstrates investor confidence in Kurma’s approach to healthcare innovation.
For further insights into FR:RF stock, check out TipRanks’ Stock Analysis page.